RAB28, member RAS oncogene family pseudogene 5Genealiases: []
Q-omics provides the consensus-scored RAB28P5 profile across patient tissues and cancer cell-line models. RAB28P5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RAB28P5 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, RAB28P5 RNA expression shows 18,961 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, LUSC, and UVM as cancer lineages where RAB28P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB28P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB28P5 survival associations across molecular data types. RAB28P5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB28P5 RNA expression–survival associations across cancer types. High RAB28P5 expression shows unfavorable associations in COAD and LIHC, but favorable associations in LUAD, KIRP, BLCA and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RAB28P5 RNA expression.
This table summarizes RAB28P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAB28P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB28P5 shows lower tumor expression in LUSC, BRCA, KICH and PRAD and higher tumor expression in LIHC and CHOL. The LUSC box plot shows higher RAB28P5 RNA expression in normal versus tumor tissue (log2 FC = −0.296, t-test p = .002).
This table shows molecular features associated with RAB28P5 in patient tissues and cancer cell lines. In patient samples, RAB28P5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
